Dr. Lester Grinspoon and many doctors support the usage of medical cannabis for Autism. The late Dr. Jeffrey Bradstreet, an autism specialist, believes autism could be a deficiency in the endocannabinoid system that causes immune system disfunction amongst other issues. The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS (Autism) [1].

Michigan recently voted to support Autism as a qualifying condition for medical cannabis. It was first state to add Autism, but probably not the last given the increasing evidence to support it’s viability as a treatement [2].

“A Novel Approach to the Symptomatic Treatment of Autism” by Lester Grinspoon M.D. (Published in O’Shaughnessy’s: The Journal of Cannabis in Clinical Practice, Spring 2010)

Autism is one of a group of conditions known as pervasive developmental disorders. This mysterious disability, first described and named over 60 years ago, is characterized by striking emotional and cognitive isolation and detachment. Continue to Study

Targeting the endocannabinoid system in the treatment of fragile X syndrome.

Fragile X syndrome (FXS), the most common monogenic cause of inherited intellectual disability and autism, is caused by the silencing of the FMR1 gene, leading to the loss of fragile X mental retardation protein (FMRP), a synaptically expressed RNA-binding protein regulating translation. Continue to Study